<?xml version="1.0" ?>
<tei type="journal-article">
	<teiHeader>
		<fileDesc xml:id="55113855"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<docTitle>
	<titlePart>Response of Factor V Inhibitor to Rituximab<lb/> in a Patient Who Received Liver Transplantation<lb/> for Primary Biliary Cirrhosis<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>Eric Chun-Yet Lian,<lb/> 1 * Andreas G. Tzakis,<lb/> 2 and David Andrews<lb/> 3<lb/></docAuthor>
	</byline>

	<byline>
	<affiliation>1 Department of Hematology/Oncology, University of Miami and Veterans Affairs Medical Center,</affiliation>
	</byline>

	<address>Miami, Florida<lb/></address>

	<byline>
	<affiliation>2 Department of Liver Transplantation, University of Miami and Veterans Affairs Medical Center,</affiliation>
	</byline>

	<address>Miami, Florida<lb/></address>

	<byline>
	<affiliation>3 Department of Pathology, University of Miami,</affiliation>
	</byline>

	<address>Miami, Florida<lb/></address>

	<div type="abstract">A 43-year-old patient developed factor V inhibitor 6 months after liver transplantation for<lb/> primary biliary cirrhosis in association with Sjö gren&apos;s syndrome/systemic lupus erythe-<lb/>matosus. She suffered from ecchymoses in the lower extremities. The factor V inhibitor<lb/> was eradicated after 10 weekly doses of 375–500 mg/m<lb/> 2 rituximab. Am.</div>

	<reference>J. Hematol.<lb/> 77:363–365, 2004. ª</reference>

	<note type="copyright">&#169;2004 Wiley-Liss, Inc.<lb/></note>

	<keyword>Key words: factor V inhibitor; rituximab; primary biliary cirrhosis; Sjö gren&apos;s syndrome;<lb/> systemic lupus erythematosus<lb/></keyword>

		</front>
	</text>
</tei>
